India: a threat to an industry or just misunderstood?

It has been a bruising few months for Western pharmaceutical companies in India. First, there was the compulsory licence awarded for Bayer’s Nexavar drug, allowing local generic company Natco Pharma to sell a version of it. In March this year, that licence was upheld on appeal, albeit in a decision requiring Natco to pay a slightly higher royalty rate.